← Back to Screener
Ligand Pharmaceuticals Inc. (LGND)
Price$229.78
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)0.61%
Price vs S&P 500 (4W)-2.98%
VGM Score51.98
Market Capitalization$4.59B
P/E Ratio (Annual)36.91x
All Metrics
P/CF (Annual)93.07x
Book Value / Share (Quarterly)$49.79
P/TBV (Annual)6.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.97%
Cash Flow / Share (Quarterly)$6.15
Price vs S&P 500 (YTD)11.75%
Gross Margin (TTM)95.27%
Net Profit Margin (TTM)55.95%
EPS (TTM)$7.42
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$7.42
Revenue Growth (5Y)7.54%
EPS (Annual)$6.13
ROI (Annual)8.50%
Gross Margin (Annual)94.57%
Net Profit Margin (5Y Avg)17.46%
Cash / Share (Quarterly)$38.91
P/E Basic Excl Extra (TTM)29.92x
Revenue Growth QoQ (YoY)14.09%
P/E Normalized (Annual)36.91x
ROA (Last FY)7.97%
Revenue Growth TTM (YoY)51.24%
EBITD / Share (TTM)$6.27
ROE (5Y Avg)4.11%
Operating Margin (TTM)34.46%
Cash Flow / Share (Annual)$2.47
P/B Ratio4.61x
P/B Ratio (Quarterly)3.99x
Net Income / Employee (Annual)$2,647,900
EV / Revenue (TTM)17.95x
Net Interest Coverage (TTM)3.08x
ROA (TTM)11.13%
EV / EBITDA (TTM)38.74x
EPS Incl Extra (Annual)$6.13
Current Ratio (Annual)22.23x
Quick Ratio (Quarterly)20.95x
3-Month Avg Trading Volume0.22M
52-Week Price Return129.87%
EV / Free Cash Flow (Annual)100.71x
P/E Incl Extra (TTM)29.92x
Revenue / Employee (TTM)$5,839,900
Tangible BV / Share (Quarterly)$29.28
P/S Ratio (Annual)17.14x
Asset Turnover (Annual)0.17x
52-Week High$247.38
Operating Margin (5Y Avg)8.09%
EPS Excl Extra (Annual)$6.13
CapEx CAGR (5Y)-36.85%
Tangible BV CAGR (5Y)41.96%
26-Week Price Return16.55%
Quick Ratio (Annual)21.98x
13-Week Price Return18.24%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)21.28x
Enterprise Value$4.93B
Revenue / Share Growth (5Y)2.80%
Asset Turnover (TTM)0.20x
Book Value / Share Growth (5Y)3.14%
Revenue / Employee (Annual)$5,704,000
Inventory Turnover (Annual)1.25x
Pretax Margin (Annual)59.29%
Cash / Share (Annual)$37.10
3-Month Return Std Dev44.80%
Gross Margin (5Y Avg)86.12%
Net Income / Employee (TTM)$3,267,200
EBITDA CAGR (5Y)8.42%
EBITDA Interim CAGR (5Y)16.83%
ROE (Last FY)12.23%
Net Interest Coverage (Annual)0.40x
EPS Basic Excl Extra (Annual)$6.13
P/FCF (TTM)37.32x
Receivables Turnover (TTM)5.97x
EV / Free Cash Flow (TTM)40.01x
Total Debt / Equity (Quarterly)0.45x
EPS Incl Extra (TTM)$7.42
Receivables Turnover (Annual)5.47x
ROI (TTM)11.97%
P/S Ratio (TTM)16.74x
Pretax Margin (5Y Avg)28.94%
Revenue / Share (Annual)$13.21
Tangible BV / Share (Annual)$30.08
Forward P/E23.54x
Free OCF CAGR (5Y)-0.48%
Price vs S&P 500 (52W)101.66%
P/E Ratio (TTM)29.92x
EPS Growth TTM (YoY)-14.89%
Year-to-Date Return22.68%
5-Day Price Return1.15%
EPS Normalized (Annual)$6.13
ROA (5Y Avg)2.84%
Net Profit Margin (Annual)46.42%
Month-to-Date Return1.09%
Cash Flow / Share (TTM)$4.86
EBITD / Share (Annual)$3.63
Operating Margin (Annual)15.29%
LT Debt / Equity (Annual)0.44x
P/CF (TTM)37.17x
ROI (5Y Avg)3.10%
P/E Excl Extra (TTM)29.92x
LT Debt / Equity (Quarterly)0.45x
EPS Basic Excl Extra (TTM)$7.42
P/TBV (Quarterly)6.79x
P/B Ratio (Annual)3.66x
Inventory Turnover (TTM)0.93x
Pretax Margin (TTM)67.36%
Book Value / Share (Annual)$51.44
Price vs S&P 500 (13W)8.50%
Beta1.23x
P/FCF (Annual)93.93x
Revenue / Share (TTM)$13.80
ROE (TTM)16.19%
52-Week Low$98.89
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 261.63est. 1.85
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.33
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LGNDLigand Pharmaceuticals Inc. | D | C | B | $229.78 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring drug technologies through strategic partnerships and licensing agreements. The company generates revenue from three primary sources: royalties on commercialized products, licensing and milestone payments, and sales of its proprietary Captisol platform.